Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.49 |
| ▸ | HTR3A | P46098 | 5/20 | 0.49 |
| ▸ | HTR3B | O95264 | 4/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21208502 | 0.84 | HTR3E (0.62) | HRH4HTR3AHTR3BHTR3EHTR3D | |
| SCHEMBL21208545 | 0.83 | HRH4 (0.54) | HRH4HTR3AHTR3BHTR3EHTR3D | |
| SCHEMBL21208503 | 0.79 | HTR3B (0.65) | HRH4HTR3AHTR3BHTR3EHTR3D | |
| SCHEMBL21208593 | 0.78 | HTR3E (0.56) | HRH4HTR3AHTR3BHTR3EHTR3D | |
| SCHEMBL21208572 | 0.78 | HRH4 (0.59) | HRH4HRH3HTR3AHTR3BHTR3E | |
| SCHEMBL21208431 | 0.78 | PTPN11 (0.38) | HRH4 | |
| SCHEMBL8117107 | 0.75 | HRH4 (0.70) | HRH4HRH3HTR3AHTR3BHTR3E | |
| SCHEMBL21208480 | 0.74 | TYMS (0.47) | — | |
| SCHEMBL21208536 | 0.72 | IKBKB (0.54) | HRH3 | |
| SCHEMBL21208524 | 0.72 | KDM4E (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317120-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2021-10-14 | — | — | US | disclosed |
| US-10975076-B2 | Compositions, uses and methods for making them | Pimera, Inc. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190233422-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | UNITED STATES GOVERNMENT | 2019-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975076-B2 | Compositions, uses and methods for making them | BAX, CASP3, CASP7 | HRH4 4472/4885HRH3 4559/4885HTR3A 3007/4885 |
| US-20190233422-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, BCL2 | HRH4 4546/4885HRH3 4489/4885HTR3A 4237/4885 |
| US-20210317120-A1 | NOVEL COMPOSITIONS, USES AND METHODS FOR MAKING THEM | BAX, CASP3, CASP7 | HRH4 4656/4885HRH3 4688/4885HTR3A 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.